Grants and Stock Movements of Major Drug Manufacturers - Research Report on AbbVie, Keryx Biopharmaceuticals, Pacira

 Grants and Stock Movements of Major Drug Manufacturers - Research Report on
 AbbVie, Keryx Biopharmaceuticals, Pacira Pharmaceuticals, Rockwell Medical,
                            and Impax Laboratories

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 22, 2013

NEW YORK, November 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting AbbVie
Inc. (NYSE: ABBV), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira
Pharmaceuticals Inc. (NASDAQ: PCRX), Rockwell Medical Inc. (NASDAQ: RMTI), and
Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

AbbVie Inc. Research Report

On November 18, 2013, AbbVie Inc. (AbbVie), along with the North Chicago
public schools, announced a grant of $350,000 for math education. According to
the Company, the grant will enable educators to strengthen and reinforce the
math curriculum for students (K-8) within the district and assist in the
implementation of an engaging, common core aligned curriculum designed to
increase both educator and student understanding of mathematics as well as
proficiency in mathematics. In a release published on the same date, the
Company also reported the first phase III results for the investigational
three direct-acting-antiviral (3D) regimen plus ribavirin in patients
chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). AbbVie
further stated that patients new to therapy receiving 12 weeks of AbbVie's 3D
regimen achieved a sustained virologic response at 12 weeks post-treatment
(SVR[12]) of 96%, during the 631-patient SAPPHIRE-I study. The Full Research
Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/273c_ABBV

--

Keryx Biopharmaceuticals Inc. Research Report

On November 19, 2013, Keryx Biopharmaceuticals Inc.'s (Keryx) stock decreased
by 1.47% to $12.40 per share. The Company's stock went down by 1.59% over the
previous three trading days, compared to the Nasdaq Composite which also went
down by 1.04% during the same period. The Full Research Report on Keryx
Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/27d2_KERX

--

Pacira Pharmaceuticals Inc. Research Report

On November 19, 2013, Pacira Pharmaceuticals Inc.'s (Pacira Pharmaceuticals)
stock was down by 1.15%, closing the day at $54.31 per share. Over the past
three trading sessions, the Company's stock went down by 0.86%, compared to
the Dow Jones Industrial Average which went up by 0.57% during the same
period. The Full Research Report on Pacira Pharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/c0aa_PCRX

--

Rockwell Medical Inc. Research Report

On November 19, 2013, Rockwell Medical Inc.'s (Rockwell Medical), formerly
known as Rockwell Medical Technologies Inc., stock went down by 0.34% closing
the trading day at $14.62 per share. Additionally, over the past three trading
days, the Company's stock reflected an increase of 4.28%, compared to the
Nasdaq Composite which in turn reflected a decrease of 1.04% within the same
trading period. The Full Research Report on Rockwell Medical Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3079_RMTI

--

Impax Laboratories Inc. Research Report

On November 19, 2013, Impax Laboratories Inc.'s (Impax Laboratories) stock
decreased by 0.13% as it closed the day with $22.82 per share. The Company's
stock also reflected a decline over the past three trading days at 1.38%,
compared to the Dow Jones Industrial Average which increased by 0.57% within
the same trading period. The Full Research Report on Impax Laboratories Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4c54_IPXL

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.